What is the Role of Streptogramins in Intensive Care?

References

• Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee JAMA. 1995; 74: 639-44.
   Google Scholar
• Periti P, Nicoletti P, De Gaudio AR et al. La chemioterapia antimicrobica nelle Unità di terapia intensiva in Italia. Farmaci Terapia 2000; 17: 161-74.
   Google Scholar
• Fridkin SK. Increasing prevalence of antimicrobial resistance in intensive care units. Crit Care Med 2001; 29 (Suppl): 64-8.
   Google Scholar
• Hiramatsu K, Aritaka N, Hanaki H et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670–3.
   Google Scholar
• Smith TL, Pearson ML, Wilcox KR et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340; 493–501.
   Google Scholar
• Ploy MG, Grelaud C, Martin C et al. First critical isolate of vancomycin–intermediate Staphylococcus aureus in a French hospital. Lancet 1998; 351: 1212.
   Google Scholar
• Cruciani M, Gatti G, Lazzarini L et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1994; 38: 865-9.
   Google Scholar
• Martin C, Alaya M, Malle MN et al. Penetration of vancomycin into mediastinal and cardiac tissues in humans. J Antimicrob Chemother 1996; 38: 865-9.
   Google Scholar
• Perry JD, Jones AL, Gould FK. Glycopeptide tolerance in bacteria causing endocarditis. J Antimicrob Chemother 1999; 44: 121–4.
   Google Scholar
• Hiramatsu K. Vancomycin resistance in staphylococci. Drug Resistance Updates 1998; 1: 135–50.
   Google Scholar
• Lamb HM, Figgitt DP, Faulds D. Quinupristin / dalfopristine: a review of its use in the management of serious Gram-positive infections. Drugs 1999; 58: 1061-97.
   Google Scholar
• Fagon J, Patrick H, Haas DW et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin / dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000; 161: 753–62.
   Google Scholar
• Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram–positive skin and skin structure infections: two randomized, multicentre studies of quinupristin / dalfopristin versus cefazolin, oxacillin or vancomycin. J Antimicrob Chemother 1999; 44: 263–73.
   Google Scholar
• Dowzicky M, Nadler HL, Ferger C et al. Evaluation of in vitro activity of quinupristin / dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates. Am J Med 1998; 104: 34S – 42S.
   Google Scholar
• Moellering RC, Linden PK, Reinhardt J et al. The efficacy and safety of quinupristin / dalfopristin for the treatment of infections caused by vancomycin–resistant Enterococcus faecium. J Antimicrob Chemother 1999; 44: 251–61.
   Google Scholar
• Goff DA, Sierawski BS. Clinical experience of quinopristin – dalfopristin for the treatment of antimicrobial-resistant gram– positive infections. Pharmacotherapy 2002; 22: 748-58.
   Google Scholar
• Sander A, Beiderlinden M, Schmid NE et al. Clinical experience with quinupristin–dalfopristin as rescue treatment of critically ill patients infected with methicillin–resistant staphylococci. Intensive Care Med 2002; 28: 1157–60.
   Google Scholar
• Messick CR, Pendland SL. In vitro activity of chloramphenicol alone and in combination with vancomycin, ampicillin, or RP 59500 (quinupristin/dalfopristin) against vancomycin- resistant enterococci. Diagn Microbiol Infect Dis 1997; 2: 203-5.
   Google Scholar
• Matsumura SO, Louie L, Louie M, Simor AE. Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents. Antimicrob Agents Chemother 1999; 43: 2776-9.
   Google Scholar
• Vouillamoz J, Entenza JM, Feger C, Glauser MP, Moreillon P. Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolidelincosamide- streptogramin B antibiotics. Antimicrob Agents Chemother 2000; 44: 1789-95.
   Google Scholar
• Saleh-Mghir A, Ameur N, Muller-Serieys C, et al. Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection. Antimicrob Agents Chemother 2002; 46: 1122.
   Google Scholar
• Sgarabotto D, Cusinato R, Narne E, et al. Synercid plus vancomycin for the treatment of severe methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci infections: evaluation of 5 cases. Scand J Infect Dis 2002; 34: 122-6.
   Google Scholar
• Viale P, Scolari C, Colombini P, Cristini F, Cadeo B, Pagani L. Sequential regimen for early post-surgical infective endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA), unresponsive to standard antibiotic therapy: a case report. J Chemother 2002; 14,6: 526-9.
   Google Scholar
• Viale P, Cristini F. Nuove prospettive terapeutiche per le infezioni da Gram-positivi multiresistenti. In: Le Infezioni batteriche in ematologia. Atti di convegno, Roma 2001. CIC Ed. Int. 2001: 91.
   Google Scholar